Tag

Exelixis Inc.

1 article

Exelixis Cabometyx Cuts Neuroendocrine Progression Risk 74%

Exelixis presented CABINET phase‑3 subgroup data showing Cabometyx reduced disease progression or death risk by 74% in non‑functional neuroendocrine tumors. Median progression‑free survival extended t